Phase 3 trials have demonstrated that enlicitide decanoate significantly reduces LDL cholesterol, showing strong potential as ...

Fintel reports that on June 18, 2025, Jefferies downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from Buy to ...

Fintel reports that on June 18, 2025, LifeSci Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

Eli Lilly is placing a bold $1.3 billion bet on Verve Therapeutics’ experimental gene-editing treatment for heart disease.